vimarsana.com

Page 38 - இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update

Share: Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2021 and provided an update on company operations. Recent Key Amarin Highlights: Q1 net total revenue : Net total revenue in the first quarter of 2021 was $142.2 million, consisting of $140.8 million in net product revenue from the United States, $0.5 million in net product revenue from outside the United States and $0.8 million in licensing and royalty revenue. Net product revenue from the United States declined $4.7 million,

Covid-19 may cause heart failure in some patients

Managing High Cholesterol and High Triglycerides

Fact-Checked High cholesterol is an extremely common problem, affecting as many as 93 million people over age 20 in the United States (about 40 percent of adults), according to the Centers for Disease Control and Prevention (CDC). But because high cholesterol has no symptoms and can only be detected with a blood test, many people may not realize they have it. High cholesterol and its close cousin high triglycerides another type of fat, or lipid, in your blood can increase your risk for heart disease and stroke, which is a problem because they’re leading causes of death in the U.S., according to the American Heart Association (AHA).

Placental infection may be more likely early in pregnancy; COVID-19 may cause heart failure in some patients

Article content The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. Placental infection may be more likely in early pregnancy We apologize, but this video has failed to load. Try refreshing your browser, or Placental infection may be more likely early in pregnancy; COVID-19 may cause heart failure in some patients Back to video The coronavirus that causes COVID-19 rarely infects the placenta, but new research suggests that when such an infection does occur it is more likely to happen early in pregnancy. Analyzing 12 placentas from healthy women, ranging in gestational age from 5 weeks to 36 weeks, researchers found that the cells in the placenta that become infected with the coronavirus have the surface protein ACE2, which the virus uses as a gateway for entry. Late in pregnancy, the ACE2 proteins are positioned on cells in a way that does not ex

MyoStrain®, MyoStress™ Rapid Hyperventilation Breath-hold Maneuver Enables First-of-its-Kind Needle-Free Stress Protocol for the Accurate Detection of Myocardial Ischemia

MORRISVILLE, N.C., April 28, 2021 /PRNewswire/  A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions ( MSI ) technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately detect myocardial ischemia. The article demonstrated MyoStrain s speed and sensitivity to successfully measure cardiac stress during a safe, simple breathing maneuver. This novel technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease without any pharmacological or physical stress protocols.[1]  Results showed the MyoStrain/MyoStress HVBH maneuver yielded greater accuracy over traditional stress testing methods for the detection of myocardial ischemia. HVBH exam times were significantly shorter and were performed without contrast agents or pharmaco

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.